Skip to main content
. Author manuscript; available in PMC: 2019 Apr 23.
Published in final edited form as: Expert Rev Vaccines. 2017 Oct 23;16(12):1203–1216. doi: 10.1080/14760584.2017.1393337

Figure 2.

Figure 2.

Global reduction in estimated measles deaths* and annual expenditures of the Measles & Rubella Initiative (M&RI) and Gavi, the Vaccine Alliance** (Gavi), 2001–2016.

Data sourced from: MMWR Morb Mortal Wkly Rep. 2016;65:1228–33. Midterm Review of the Measles and Rubella Global Strategic Plan 2012–2020.

*In 2010, the World Health Assembly established three milestones for measles control by 2015: 1) increase routine coverage with the first dose of measles-containing vaccine for children aged 1 year to ?90% nationally and ?80% in every district; 2) reduce global annual measles incidence to <5 cases per million population; and 3) reduce global measles mortality by 95% from the 2000 estimate.

**Represents measles-related Gavi expenditures. Not shown here, approximately US$800 million available to Gavi-eligible countries during 2016–2020, approved by the Gavi Board in December 2015, as part of a new Gavi comprehensive measles and rubella strategy.